Zomig

See also: Generic Zomig-ZMT

Zomig is a brand name of zolmitriptan, approved by the FDA in the following formulation(s):

ZOMIG (zolmitriptan - spray; nasal)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: September 30, 2003
  
  Strength(s): 5MG/SPRAY ^[RLD]

ZOMIG (zolmitriptan - tablet; oral)

• 
  Manufacturer: IPR
  
  Approval date: November 25, 1997
  
  Strength(s): 2.5MG, 5MG ^[RLD]

Has a generic version of Zomig been approved?

No. There is currently no therapeutically equivalent version of Zomig available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Indolyl compounds for treating migraine
  Patent 5,466,699
  Issued: November 14, 1995
  Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
  Assignee(s): Burroughs Wellcome Co.
  ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
  
  Patent expiration dates:
  
  
  • November 14, 2012
    
  
  
  
  • November 14, 2012
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  
  
  • May 14, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Therapeutic heterocyclic compounds
  Patent 5,863,935
  Issued: January 26, 1999
  Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
  Assignee(s): Zeneca Limited
  ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
  
  Patent expiration dates:
  
  
  • November 14, 2012
    
  
  
  
  • May 14, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations containing zolmitriptan
  Patent 6,750,237
  Issued: June 15, 2004
  Inventor(s): Alan Roy; Dearn & Sarah Louise; Williamson & Simon John; Summers & Trevor John; Coomber
  Assignee(s): AstraZeneca AB
  A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
  
  Patent expiration dates:
  
  
  • November 28, 2020
    
    ✓ 
    Drug product
  
  
  
  • May 28, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations containing zolmitriptan
  Patent 7,220,767
  Issued: May 22, 2007
  Inventor(s): Dearn; Alan Roy & Williamson; Sarah Louise & Summers; John Simon & Coomber; Trevor John
  Assignee(s): AstraZeneca AB
  A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
  
  Patent expiration dates:
  
  
  • November 28, 2020
    
    ✓ 
    Drug product
  
  
  
  • May 28, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zomig Consumer Information (Drugs.com)
• Zomig Consumer Information (Wolters Kluwer)
• Zomig Spray Consumer Information (Wolters Kluwer)
• Zomig Consumer Information (Cerner Multum)
• Zomig nasal Consumer Information (Cerner Multum)
• Zomig Advanced Consumer Information (Micromedex)
• Zomig AHFS DI Monographs (ASHP)
• Zolmitriptan Consumer Information (Wolters Kluwer)
• Zolmitriptan Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Zolmitriptan Spray Consumer Information (Wolters Kluwer)
• Zolmitriptan Consumer Information (Cerner Multum)
• Zolmitriptan nasal Consumer Information (Cerner Multum)
• Zolmitriptan Advanced Consumer Information (Micromedex)
• Zolmitriptan AHFS DI Monographs (ASHP)